{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:00:03Z","timestamp":1793505603527,"version":"4.5.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Low adherence to statin therapy remains a public health concern associated with poor prognosis in cardiovascular disease patients. A feasible method for statin adherence monitoring in clinical practice has yet to be developed. In this article, we describe a novel method designed for the direct monitoring of atorvastatin adherence based on the sum of parent drug and major metabolites in blood samples.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Acid and lactone forms of atorvastatin, 2-OH-atorvastatin, and 4-OH-atorvastatin were assayed. Plasma proteins were precipitated with an acidified mixture of methanol, acetonitrile, and aqueous zinc sulfate, and the supernatant was analyzed with 2-channel reversed-phase chromatography coupled to tandem mass spectrometry. Assay validation was performed according to the guidelines provided by the European Medicines Agency and the US Food and Drug Administration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The effective run time was 1 minute and 45 seconds per sample. Mean accuracy ranged from 92% to 110%, and coefficients of variation were \u22648.1% over the measurement ranges for individual compounds. The sum of acids and corresponding lactones was stable in clinical plasma samples kept at ambient temperature for up to 6 days after blood sampling (mean sum within 96.6%\u2013101% of baseline).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>A fast and reliable assay for the quantification of atorvastatin and its 5 major metabolites in clinical blood samples is reported. Limitations of preanalytical stability were solved using the sum of the acid and lactone forms. The assay is feasible for implementation in clinical practice, and the sum of parent drug and metabolites may be used for direct monitoring of atorvastatin adherence.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000578","type":"journal-article","created":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T20:26:19Z","timestamp":1543609579000},"page":"19-28","source":"Crossref","is-referenced-by-count":26,"title":["A Method for Direct Monitoring of Atorvastatin Adherence in Cardiovascular Disease Prevention: Quantification of the Total Exposure to Parent Drug and Major Metabolites Using 2-Channel Chromatography and Tandem Mass Spectrometry"],"prefix":"10.1097","volume":"41","author":[{"given":"Nils Tore","family":"Vethe","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Oslo University Hospital, Oslo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Munkhaugen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Drammen Hospital, Vestre Viken Trust, Drammen;"},{"name":"Department of Behavioural Science in Medicine, Faculty of Medicine, University of Oslo, Oslo; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders M.","family":"Andersen","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Oslo University Hospital, Oslo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Husebye","sequence":"additional","affiliation":[{"name":"Department of Medicine, Drammen Hospital, Vestre Viken Trust, Drammen;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stein","family":"Bergan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Oslo University Hospital, Oslo;"},{"name":"School of Pharmacy, University of Oslo, Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology\/American heart association task force on practice guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European association for cardiovascular prevention & rehabilitation (EACPR)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/ehjci\/jet251","article-title":"Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN","volume":"15","author":"Puri","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1161\/CIRCULATIONAHA.115.018381","article-title":"Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT","volume":"132","author":"Bohula","year":"2015","journal-title":"Circulation."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0140-6736(09)60330-5","article-title":"Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries","volume":"373","author":"Kotseva","year":"2009","journal-title":"Lancet."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1177\/2047487317693134","article-title":"Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients","volume":"24","author":"Munkhaugen","year":"2017","journal-title":"Eur J Prev Cardiol."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/jama.297.2.177","article-title":"Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction","volume":"297","author":"Rasmussen","year":"2007","journal-title":"JAMA."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3109\/08037051.2015.1121706","article-title":"Adherence to medication and drug monitoring in apparent treatment-resistant hypertension","volume":"25","author":"Eskas","year":"2016","journal-title":"Blood Press."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1161\/CIRCULATIONAHA.113.002658","article-title":"Racial\/ethnic and gender gaps in the use of and adherence to evidence-based preventive therapies among elderly Medicare part D beneficiaries after acute myocardial infarction","volume":"129","author":"Lauffenburger","year":"2014","journal-title":"Circulation."},{"key":"R12-20230814","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000011.pub4","article-title":"Interventions for enhancing medication adherence","author":"Nieuwlaat","year":"2014","journal-title":"Cochrane Database Syst Rev."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jacc.2013.10.067","article-title":"Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension","volume":"63","author":"Brinker","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.4155\/bio.15.163","article-title":"Cardiovascular drug determination in bioanalysis: an update","volume":"7","author":"Gonzalez","year":"2015","journal-title":"Bioanalysis."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jchromb.2014.12.029","article-title":"Liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of simvastatin, lovastatin, atorvastatin, and their major metabolites in human plasma","volume":"983\u2013984","author":"Wang","year":"2015","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jsha.2014.04.005","article-title":"Which statin worked best to achieve lipid level targets in a European registry? A post-hoc analysis of the EUROASPIRE III for coronary heart disease patients","volume":"26","author":"Alnouri","year":"2014","journal-title":"J Saudi Heart Assoc."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin Pharmacol Ther."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1517\/17425255.2016.1163337","article-title":"Cyp3a activity: towards dose adaptation to the individual","volume":"12","author":"Hohmann","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1124\/dmd.30.5.505","article-title":"Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization","volume":"30","author":"Prueksaritanont","year":"2002","journal-title":"Drug Metab Dispos."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1007\/s00216-005-3266-5","article-title":"Determination of atorvastatin and metabolites in human plasma with solid-phase extraction followed by LC-tandem MS","volume":"382","author":"Hermann","year":"2005","journal-title":"Anal Bioanal Chem."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jpha.2013.09.007","article-title":"Simultaneous quantitation of atorvastatin and its two active metabolites in human plasma by liquid chromatography\/(-) electrospray tandem mass spectrometry","volume":"4","author":"Partani","year":"2014","journal-title":"J Pharm Anal."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"333","DOI":"10.4155\/bio.15.245","article-title":"Development of MEPS-UHPLC-MS\/MS multistatin methods for clinical analysis","volume":"8","author":"Vlckova","year":"2016","journal-title":"Bioanalysis."},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/jssc.201401227","article-title":"High-throughput salting-out-assisted liquid-liquid extraction for the simultaneous determination of atorvastatin, ortho-hydroxyatorvastatin, and para-hydroxyatorvastatin in human plasma using ultrafast liquid chromatography with tandem mass spectrometry","volume":"38","author":"Yang","year":"2015","journal-title":"J Sep Sci."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jchromb.2013.01.001","article-title":"Simultaneous determination of amlodipine and atorvastatin with its metabolites; ortho and para hydroxy atorvastatin; in human plasma by LC-MS\/MS","volume":"917\u2013918","author":"Yacoub","year":"2013","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jpba.2013.04.021","article-title":"Development and validation of a liquid chromatography-tandem mass spectrometry method for simultaneous determination of amlodipine, atorvastatin and its metabolites ortho-hydroxy atorvastatin and para-hydroxy atorvastatin in human plasma and its application in a bioequivalence study","volume":"83","author":"Zhou","year":"2013","journal-title":"J Pharm Biomed Anal."},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.clpt.2006.02.014","article-title":"Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy","volume":"79","author":"Hermann","year":"2006","journal-title":"Clin Pharmacol Ther."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201902000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:15:07Z","timestamp":1692051307000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201902000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000578","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}